Astellas Pharma Inc

Read how Astellas’ $120 M settlement with Zydus keeps Myrbetriq’s patent strong, defends pricing, and protects future revenue.

How Astellas’ Mirabegron settlement with Lupin delays U.S. generics and protects $300 M in revenue.

Explore Astellas Pharma’s analyst outlook, partnership strategy, and clinical pipeline to understand its growth potential and impact on patient access.

Discover how Astellas Pharma’s R&D‑focused strategy, global pipeline in oncology, metabolic disease and immunology, and proactive M&A plans aim to navigate patent cliffs and fierce competition while driving steady revenue growth.

Discover how Astellas Pharma’s upcoming JP Morgan Healthcare Conference talks reveal new immuno‑oncology breakthroughs, rare‑disease gene therapies, and growth strategies amid regulatory and competitive challenges.

Explore how Astellas’ new GI oncology data and market strategy can drive growth in gastric cancer treatment and broader therapeutic segments.

Discover how Astellas Pharma’s precision‑medicine pipeline—targeting ovarian cancer, chordoma, GI oncology and more—drives global growth, market expansion and innovative partnerships.

Explore Astellas Pharma’s Q2 2026 & FY 2025 earnings transcripts—see how its urology, oncology, immunology and metabolic therapies drive growth, R&D investment, and strategic roadmap.

Astellas Pharma Inc. has announced positive results from a Phase IV clinical trial of fezolinetant for menopausal symptoms and received FDA priority review for PADCEV in muscle-invasive bladder cancer, driving an upward trend in the company’s share …

Astellas Pharma Inc. has reported positive clinical trial results and strategic advancements in its therapeutic areas, positioning the company for long-term success in the pharmaceutical market.